Fisetin inhibits matrix metalloproteinases and reduces tumor cell invasiveness and endothelial cell tube formation

Nutrition and Cancer

Volumn 65, Issue 8, 2013, Pages 1192-1199

  Park, Jun Hyoung ^a   Jang, Yoon Jung ^a   Choi, Yu Jung ^a   Jang, Jin Wook ^a   Kim, Joo Hyon ^a   Rho, Yang Kook ^b   Kim, In Ja ^c   Kim, Hwa Jung ^c   Leem, Moon Jeong ^b   Lee, Seung Taek ^a  

^a Yonsei University   (South Korea)

^b DongWha Pharm Ind Co   (South Korea)

^c Ewha Womans University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FISETIN; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; STROMELYSIN; TETRACYCLINE;

ARTICLE; CHEMOPROPHYLAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DALBERGIA; DALBERGIA ODORIFERA; DRUG EFFECT; DRUG INHIBITION; DRUG SELECTIVITY; ENDOTHELIUM CELL; ENZYME ACTIVE SITE; ENZYME INHIBITION; FIBROSARCOMA; FRACTIONATION; FRUIT; HUMAN; HUMAN CELL; PLANT ROOT; TUMOR INVASION; UMBILICUS; VEGETABLE;

DALBERGIA ODORIFERA; FABACEAE;

APOLIPOPROTEINS E; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOPREVENTION; DALBERGIA; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME PRECURSORS; FLAVONOIDS; GELATINASES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; PLANT EXTRACTS; PLANT ROOTS;

EID: 84888331607     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2013.828090     Document Type: Article

References (30)

1. Woessner JF Jr: MMPs and TIMPs: an historical perspective. Mol Biotechnol 22, 33-49, 2002.
2. Nelson AR, Fingleton B, Rothenberg ML, and Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18, 1135-1149, 2000.
3. Coussens LM, Fingleton B, and Matrisian LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392, 2002.
4. Golub LM, Sorsa T, Lee HM, Ciancio S, Sorbi D, et al.: Doxycycline inhibits neutrophil (PMN)-type matrix metalloproteinases in human adult periodontitis gingiva. J Clin Periodontol 22, 100-109, 1995.
5. Ryan ME, Ramamurthy S, and Golub LM: Matrix metalloproteinases and their inhibition in periodontal treatment. Curr Opin Periodontol 3, 85-96, 1996.
6. Koo HM, Kim JH, Hwang IK, Lee SJ, Kim TH, et al.: Refolding of the catalytic and hinge domains of human MT1-MMP expressed in Escherichia coli and its characterization. Mol Cells 13, 118-124, 2002.
7. Kim SY, Park SM, and Lee S-T: Apolipoprotein C-II is a novel substrate for matrix metalloproteinases. Biochem Biophys Res Commun 339, 47-54, 2006.
8. Choi S-S, Ji A-R, Yu S-W, Cho B-H, Park JD, et al.: Inhibition of invasion and capillary-like tube formation by retrohydroxamate-based MMP inhibitors. Bull Korean Chem Soc 32, 2032-2038, 2011.
9. Jo Y, Yoon D-W, Kim MY, Lee YJ, Kim HJ, et al.: Tissue inhibitor of metalloproteinases-2 inhibits the 4-aminophenylmercuric acetate-induced activation and autodegradation of the free promatrix metalloproteinase-2. J Biolchem Mol Biol 32, 60-66, 1999.
10. Park SM, Hwang IK, Kim SY, Lee SJ, Park KS, et al.: Characterization of plasma gelsolin as a substrate for matrix metalloproteinases. Proteomics 6, 1192-1199, 2006.
11. Golub LM, Ramamurthy N, McNamara TF, Gomes B, Wolff M, et al.: Tetracyclines inhibit tissue collagenase activity. A new mechanism in the treatment of periodontal disease. J Periodontal Res 19, 651-655, 1984.
12. Hurewitz AN, Wu CL, Mancuso P, and Zucker S: Tetracycline and doxycycline inhibit pleural fluid metalloproteinases. A possible mechanism for chemical pleurodesis. Chest 103, 1113-1117, 1993.
13. Jaffe EA, Nachman RL, Becker CG, and Minick CR: Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52, 2745-2756, 1973.
14. Hansen MB, Nielsen SE, and Berg K: Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119, 203-210, 1989.
15. Shin WS, Maeng YS, Jung JW, Min JK, Kwon YG, et al.: Soluble PTK7 inhibits tube formation, migration, and invasion of endothelial cells and angiogenesis. Biochem Biophys Res Commun 371, 793-798, 2008.
16. Park JH, Park SM, Park SH, Cho KH, and Lee S-T: Cleavage and functional loss of human apolipoprotein E by digestion of matrix metalloproteinase-14. Proteomics 8, 2926-2935, 2008.
17. Yu M, Sato H, Seiki M, Spiegel S, and Thompson EW: Elevated cyclic AMP suppresses ConA-induced MT1-MMP expression in MDA-MB-231 human breast cancer cells. Clin Exp Metastasis 16, 185-191, 1998.
18. Jiang A, Lehti K, Wang X, Weiss SJ, Keski-Oja J, et al.: Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis. Proc Natl Acad Sci USA 98, 13693-13698, 2001.
19. KessenbrockK, PlaksV, andWerb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52-67, 2010.
20. Liotta LA, Steeg PS, and Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64, 327-336, 1991.
21. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, et al.: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370, 61-51, 1994.
22. Knauper V, Will H, Lopez-Otin C, Smith B, Atkinson SJ, et al.: Cellular mechanisms for human procollagenase-3 activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem 271, 17124-17131, 1996.
23. Nagakawa O, Murakami K, Yamaura T, Fujiuchi Y, Murata J, et al.: Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines. Cancer Lett 155, 173-179, 2000.
24. Seiki M, and Yana I: Roles of pericellular proteolysis by membrane type-1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Sci 94, 569-574, 2003.
25. Lim DY and Park JHY: Induction of p53 contributes to apoptosis of HCT-116 human colon cancer cells induced by the dietary compound fisetin. Am J Physiol Gastrointest Liver Physiol 296, G1060-G1068, 2009.
26. Li J, Cheng Y, Qu W, Sun Y, Wang Z, et al.: Fisetin, a dietary flavonoid, induces cell cycle arrest and apoptosis through activation of p53 and inhibition of NF-kappa B pathways in bladder cancer cells. Basic Clin Pharmacol Toxicol 108, 84-93, 2011.
27. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, et al.: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284, 67-68, 1980.
28. Karakiulakis G, Papanikolaou C, Jankovic SM, Aletras A, Papakonstantinou E, et al.: Increased type IV collagen-degrading activity in metastases originating from primary tumors of the human colon. Invasion Metastasis 17, 158-168, 1997.
29. Folkman J: Fighting cancer by attacking its blood supply. Sci Am 275, 150-154, 1996.
30. Schnaper HW, Grant DS, Stetler-Stevenson WG, Fridman R, D'Orazi G, et al.: Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol 156, 235-246, 1993.